Hematologic Malignancies
News
Cancer Patients: Who’s at Risk for Venous Thromboembolism?
Conference Coverage
Gilteritinib maintenance reduces relapse in MRD+ AML
Despite not meeting its primary endpoint, a trial in mutated acute myeloid leukemia showed the benefit of gilteritinib maintenance in certain...
Conference Coverage
CLL: Venetoclax-obinutuzumab combo effective long term
Progression-free survival benefit of 1 year with venetoclax-obinutuzumab is sustained long term in chronic lymphocytic leukemia, trial analysis...
News
FDA approves glofitamab for DLBCL
Glofitamab, a T cell–engaging bispecific antibody, has been approved by the Food and Drug Administration for adults with DLBCL.
News
Ibrutinib + venetoclax: High-risk features don’t lessen CLL response
Expert cautions that upfront targeted therapies for CLL should be considered experimental, given the adverse events and lack of long-term follow-...
News
Widespread carboplatin, cisplatin shortages: NCCN survey
Only 64% of centers said they are still able to continue treating all current patients receiving carboplatin.
Conference Coverage
`Remarkable’: CAR T therapy for CLL/SLL
Primary analysis of the TRANSCEND CLL 004 trial showed that a single dose of CAR T therapy achieved durable responses in CLL and SLL, with a...
Conference Coverage
PMBCL: Postremission, patients may safely skip radiation
Among patients who had achieved complete remission of primary mediastinal B-cell lymphoma with chemotherapy, the largest study of its kind found...
News
New CLL meds: Improved survival rates, 1990-2018
A just-published retrospective study shows nearly 30 years of steady progress in lengthening the lives of U.S. adults with CLL and other leukemias...
Latest News
Cross-border U.S.-Mexican collaboration drives up ALL survival